S. A. Lund
Harvard University
5 Papers
146 Citations
S. A. Lund is an academic researcher from Harvard University. The author has contributed to research in topics: Calcification & Controlled release. The author has an hindex of 5, co-authored 5 publications. Previous affiliations of S. A. Lund include Boston Children's Hospital & University of Michigan.
Chat about Author
Papers
Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate
TL;DR: In the present study, inhibition of the calcification of bioprosthetic heart valve cusps implanted subcutaneously in rats was achieved through the adjacent implantation of controlled-release matrices containing the anticalcification agent ethanehydroxydiphosphonate dispersed in a copolymer of ethylene-vinyl acetate.
431
•Journal Article
Calcification of subcutaneously implanted type I collagen sponges. Effects of formaldehyde and glutaraldehyde pretreatments.
TL;DR: It is concluded that both glutaraldehyde- and formaldehyde-pretreated Type I collagen sponges calcify after subdermal implantation in young rats, and the threshold level of aldehyde-induced cross-linking required to potentiate their maximal pathologic calcification is low.
139
Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats.
TL;DR: It is concluded that diphosphonates inhibit BC calcification, and that adverse effects of systemic therapy can be avoided by local administration.
84
Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations.
Robert J. Levy,Robert J. Levy,Robert J. Levy,Frederick J. Schoen,Frederick J. Schoen,Frederick J. Schoen,S. A. Lund,S. A. Lund,S. A. Lund,Mary Sue Smith,Mary Sue Smith,Mary Sue Smith +11 more
TL;DR: It is concluded that ethanehydroxydiphosphonate optimally prevents bioprosthetic heart valve calcification without significant adverse effects on epiphyseal development and overall somatic growth at a dosage of 10 mg/kg/24 hr in rat subdermal implants, but it must be administered by continuous daily injections beginning within 48 hours of the implantation.
59